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treatment in patients with HIV infection and 
extrapulmonary or MDR tuberculosis. We have 
no reason to suspect that MDR tuberculosis was 
unequally distributed in SAPIT study groups, 
since patients were randomly assigned to treat-
ment and patients with previous tuberculosis at 
high risk for resistance were evenly distributed 
among the study groups.
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Tuberculosis	Screening	and	Diagnosis	in	People	with	HIV
To the Editor: Cain et al. (Feb. 25 issue)1 con-
clude that screening for tuberculosis in people 
with human immunodeficiency virus (HIV) in-
fection should include questions about a combi-
nation of symptoms rather than just chronic 
cough. They suggest that the recently published 
World Health Organization (WHO) approach2 
for the diagnosis of tuberculosis among people 
with HIV has a sensitivity of less than 33%. How-
ever, they restrict the WHO approach to the di-
agnosis of pulmonary tuberculosis and do not 
consider extrapulmonary tuberculosis. For extra-
pulmonary tuberculosis, the WHO recommends 
taking into account other characteristics, such as 
weight loss, fever, and night sweats. We agree, 
however, that the use of the three screening cri-
teria (cough of any duration, fever of any dura-
tion, and night sweats lasting 3 or more weeks in 
the preceding 4 weeks) proposed by Cain et al. 
simplifies the screening and diagnosis of pulmo-
nary and extrapulmonary tuberculosis and will 
facilitate the implementation of screening and 
diagnosis at the country level.
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The Authors Reply: Koole and colleagues note 
that our analysis of the WHO approach to tuber-
culosis screening in people with HIV did not 
address extrapulmonary tuberculosis. The WHO 
has guidelines for the diagnosis of extrapulmo-
nary tuberculosis but no explicit guidelines re-
garding screening.1 The guidelines include sev-
eral symptoms that might prompt a clinician to 
consider extrapulmonary tuberculosis, but there 
is no explicit recommendation to screen for them 
in all patients or to trigger a diagnostic evalua-
tion for tuberculosis when one of them is pres-
ent. Chronic cough is the only symptom explic-
itly noted for routine tuberculosis screening.1
We reported on symptom screening when pa-
tients with all types of tuberculosis were included. 
We analyzed the data again after excluding the 
25 patients who had only extrapulmonary tubercu-
losis. The sensitivity of cough lasting 2 to 3 weeks 
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or more for the detection of culture-proven pul-
monary tuberculosis remained low (23 to 34%). 
Thus, inclusion of patients with extrapulmonary 
tuberculosis does not explain the low sensitivity 
of chronic cough.
In contrast, the symptom combination that 
we proposed had a sensitivity of 93% for the 
detection of pulmonary and extrapulmonary 
tuberculosis and, therefore, can be used to rule 
out tuberculosis in all people with HIV in-
fection.
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Prophylactic	Platelet	Transfusions
To the Editor: Slichter et al. (Feb. 18 issue)1 re-
port on the results of the platelet-dose (PLADO) 
trial (ClinicalTrials.gov number, NCT00128713). 
To interpret the results of this study accurately, it 
would be very important to know the ABO com-
patibility between recipients and platelet transfu-
sions. A major ABO incompatibility can decrease 
the response to a platelet transfusion by between 
23% and 41% in patients with hematologic can-
cers.2 A platelet transfusion with minor ABO in-
compatibility is also associated with a decrease 
in the post-transfusion increment, perhaps be-
cause of immune complexes.3 Others have also 
reported that ABO compatibility is associated 
with an increase in the recovery at 1 hour but not 
at 24 hours.4 Moreover, a previous meta-analysis 
of studies that examined the effect of the trans-
fusion platelet dose on several variables showed 
that when the studies that guaranteed ABO com-
patibility of the platelet transfusions were com-
bined, high doses of platelets were associated 
with a significant increase in the post-transfu-
sion increment as compared with low doses of 
platelets (weighted mean difference, 23.6×109 
platelets per liter; 95% confidence interval, 
18.28×109 to 28.92×109 per liter; P<0.001).5
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To the Editor: Slichter et al. report that at doses 
between 1.1×1011 and 4.4×1011 platelets per square 
meter, the number of platelets in the prophylactic 
transfusion had no effect on the incidence of 
bleeding in hospitalized patients undergoing 
hematopoietic stem-cell transplantation or chemo-
therapy for hematologic cancers or solid tumors. 
Although the authors accounted for some con-
founders (e.g., serum fibrinogen, activated partial-
thromboplastin time, prothrombin time, and acute 
promyelocytic leukemia), they did not account for 
other relevant risk factors for bleeding, such as 
mucosal or vascular infiltration by solid tumors, 
chemotherapy-induced gastrointestinal mucositis, 
graft-versus-host disease,1 hemorrhagic cystitis,2 
and veno-occlusive disease after allogeneic hema-
topoietic stem-cell transplantation.3
Finally, although they did not directly account 
for bleeding events, the number of required plate-
let transfusions could be related to post-transfu-
sion increments, which are known to be higher 
when platelets are stored for less than 6 days.4
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